Data gathered: July 26
Alternative Data for Novo Nordisk
About Novo Nordisk
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.
![Novo Nordisk](https://altindex.com/assets/images/tickers/NVO.jpg)
Price | $126.73 |
Target Price | Sign up |
Volume | 3,130,000 |
Market Cap | $572B |
Year Range | $95.52 - $146.91 |
Dividend Yield | 1.04% |
PE Ratio | 44.28 |
Industry | Drug Manufacturers |
In the news
![]() |
Ozempic-producer Novo Nordisk on track for record spending on lobbying in 2024July 26 - Raw Story |
![]() |
Novo Nordisk's Wegovy wins EU backing for reducing heart risksJuly 26 - CNBC |
![]() |
Why Viking’s Weight-Loss Drug News Is Weighing on Eli Lilly, Novo Nordisk StocksJuly 25 - Investopedia |
![]() |
An Ozempic rival is getting closer to market — and it's hurting Novo Nordisk and Eli Lilly stockJuly 25 - Quartz India |
![]() |
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo NordiskJuly 25 - Investor's Business Daily |
![]() |
Viking’s stock pops as obesity-drug contender drags down Eli Lilly, Novo NordiskJuly 25 - Biztoc.com |
Financial performance View All
Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
---|---|---|---|---|---|---|
Q1 '24 | 65.3B | 9.92B | 55.4B | 25.4B | 35.3B | 0.830 |
Q4 '23 | 65.9B | 10B | 55.8B | 22B | 28.5B | 0.710 |
Q3 '23 | 58.7B | 9.71B | 49B | 22.5B | 32.8B | 0.730 |
Q2 '23 | 54.3B | 7.86B | 46.4B | 19.4B | 26.7B | 0.670 |
Q1 '23 | 53.4B | 8.18B | 45.2B | 19.8B | 27.6B | 0.630 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Company | Price | AI Score | |
---|---|---|---|
![]() |
Johnson & JohnsonJNJ |
$160.64 0.6% | 53 |
![]() |
Eli Lilly and CompanyLLY |
$804.62 2% | 61 |
![]() |
PfizerPFE |
$30.77 2% | 42 |
![]() |
AstrazenecaAZN |
$78.13 0.5% | 63 |
![]() |
AbbVieABBV |
$185.16 1.6% | 63 |
Congress Trading View All
Politician | Filing Date | Type | Size |
---|---|---|---|
Michael McCaul |
Jun 20, 24 | Buy | $15K - $50K |
Michael McCaul |
Jun 20, 24 | Buy | $15K - $50K |
Michael McCaul |
Jun 20, 24 | Buy | $15K - $50K |
Read more about Novo Nordisk (NVO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Novo Nordisk?
The Market Cap of Novo Nordisk is $572B.
What is Novo Nordisk's PE Ratio?
As of today, Novo Nordisk's PE (Price to Earnings) ratio is 44.28.
What is the current stock price of Novo Nordisk?
Currently, the price of one share of Novo Nordisk stock is $126.73.
How can I analyze the NVO stock price chart for investment decisions?
The NVO stock price chart above provides a comprehensive visual representation of Novo Nordisk's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novo Nordisk shares. Our platform offers an up-to-date NVO stock price chart, along with technical data analysis and alternative data insights.
Does NVO offer dividends to its shareholders?
Yes, Novo Nordisk (NVO) offers dividends to its shareholders, with a dividend yield of 1.04%. This dividend yield represents Novo Nordisk's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Novo Nordisk in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Novo Nordisk?
Some of the similar stocks of Novo Nordisk are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.